Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

By J. Rossouw, G. Anderson, Ross L. Prentice, Andrea Z. LaCroix, Charles L. Kooperberg, Marcia L. Stefanick, R. Jackson, S. A. Beresford, Barbara V. Howard, Karen C. Johnson and 2 more. 2002

15,285 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Public Health, Environmental and Occupational Health

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Sebastian Schneeweiss
2. A. Jemal
3. G. Gillies
4. S. McArthur
5. R. Siegel
6. A. Hevener

In Genetics

1. Sebastian Schneeweiss
2. F. Bray
3. A. Jemal
4. J. Ferlay
5. G. Gillies
6. Rhoda Au
7. James W. Vaupel
8. David Freedman

In Public Health, Environmental and Occupational Health

1. Holger J. Schünemann
2. G. Guyatt
3. R. Siegel
4. Andrew D. Oxman
5. A. Jemal
6. G. Vist
7. G. Gillies
8. David Freedman

Citations in the corpus

• Frailty syndrome: an overview (2014, neutral): “Estrogen-replacement therapy in postmenopausal women also has an unfavorable safety profile.(91) Friedlander et al reported that IGF-1 therapy had a beneficial impact on bone density, muscle strength, or physical function in elderly women with no clinical IGF-1 deficiency.”